2-[2-(4-氯苯基)乙氧基]腺苷 | 131865-88-8

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 中文名称: 2-[2-(4-氯苯基)乙氧基]腺苷
• 英文名称: MRE 0094
• 英文别名: Sonedenoson；(2R,3R,4S,5R)-2-[6-amino-2-[2-(4-chlorophenyl)ethoxy]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
• CAS: 131865-88-8
• 化学式: C₁₈H₂₀ClN₅O₅
• 分子量: 421.84
• InChiKey: WUCQGGOGHZRELS-LSCFUAHRSA-N

物化性质

• 熔点：
  175-176°C
• 密度：
  1.72
• 溶解度：
  可溶于DMSO（略微加热）、甲醇（略微加热）

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  149
• 氢给体数：
  4
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  4-氯苯乙醇 在 正丁基锂 、 甲酸 、 溶剂黄146 作用下， 以 水 为溶剂， 反应 2.25h， 生成 2-[2-(4-氯苯基)乙氧基]腺苷
  参考文献：
  名称：

  2-Aralkoxyadenosines: potent and selective agonists at the coronary artery A2 adenosine receptor

  摘要：

  A Langendorff guinea pig heart preparation served for the assay of agonist potency of a series of 26 2-aralkoxyadenosines at the A1 and A2 receptors of, respectively, the atrioventricular node (conduction block) and coronary arteries (vasodilation). All of the analogues are weak agonists at the A1 receptor, requiring concentrations > 9-mu-M to cause second degree heart block. At the A2 receptor 2-phenethoxyadenosine is the most potent of the 2-phenylalkyladenosines. The activity of ring-substituted (F, Cl, CH3, and OCH3) 2-phenethoxyadenosines increases ortho < meta < para. The EC50s of coronary vasoactivity of several para-substituted analogues are in the subnanomolar range. The most potent analogue, 2-[2-(4-methylphenyl)ethoxy]adenosine 19, has an EC50 for coronary vasodilation of 190 pM and an A1/A2 selectivity ratio of 44000. Aryl groups such as thienyl, indoloyl, or naphthyl also support A2 agonist activity. Although 2-oxoadenosine is 3 times more vasoactive than 2-aminoadenosine, the activities of the phenyl derivatives are markedly different; 2-phenoxyadenosine is 23 times weaker than 2-(phenylamino)adenosine (CV-1808).

  DOI：

  10.1021/jm00108a015

文献信息

• DENDRIMER CONJUGATES OF AGONISTS AND ANTAGONISTS OF THE GPCR SUPERFAMILY
  申请人：Jacobson Kenneth A.

  公开号：US20090012035A1

  公开（公告）日：2009-01-08

  Disclosed are conjugates comprising a dendrimer and a ligand, which is a functionalized congener of an agonist or antagonist of a receptor of the G-protein coupled receptor (GPCR) superfamily, for example, wherein the functionalized congener is an A 1 adenosine receptor agonist having a purine nucleoside moiety and a functional group at the N 6 position of the purine nucleoside moiety, wherein the functional group has the formula (I): N 6 H—Ar 1 —CH 2 —C(═O)NH—R 1 (I), wherein Ar 1 and R 1 as defined herein. Also disclosed are pharmaceutical compositions, methods of treating various diseases, and a diagnostic method employing such conjugates.

  本文披露了包含树状聚合物和配体的共轭物，其中配体是G-蛋白偶联受体（GPCR）超家族受体的激动剂或拮抗剂的官能化同系物，例如，其中官能化同系物是具有嘌呤核苷酸基团和在嘌呤核苷酸基团的N6位置上具有官能基的A1腺苷受体激动剂，其中官能基具有以下结构式（I）：N6H—Ar1—CH2—C(═O)NH—R1（I），其中Ar1和R1如本文所定义。还披露了包括制药组合物、治疗各种疾病的方法以及使用这种共轭物的诊断方法。
• Synthesis of 2-aralkoxyadenosines and 2-alkoxyadenosines
  申请人：——

  公开号：US20030199686A1

  公开（公告）日：2003-10-23

  The invention provides new methods for synthesis of 2-aralkyloxyadenosines and 2-alkoxyadenosines. The invention is particularly useful for synthesis of 2-[2-(4-chlorophenyl)ethoxy]adenosine. Preferred methods of the invention include activating a guanosine compound followed by hydrolysis; alkylating the hydrolyzed compound with subsequent animation to provide a 2-aralkyloxyadenosine or a 2-alkoxyadenosine compound.

  这项发明提供了合成2-芳基氧基腺苷和2-烷氧基腺苷的新方法。该发明特别适用于合成2-[2-(4-氯苯基)乙氧基]腺苷。该发明的首选方法包括激活鸟苷化合物，然后进行水解；烷基化水解后的化合物，随后进行胺化，以提供2-芳基氧基腺苷或2-烷氧基腺苷化合物。
• [EN] P2Y1 RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RÉCEPTEURS P2Y1
  申请人：US HEALTH

  公开号：WO2009152431A1

  公开（公告）日：2009-12-17

  The invention provides P2Y1 receptor antagonists of Formula (I); wherein R1-R3 are as defined in the specification, pharmaceutical compositions comprising the same, and the use of such antagonists in the treatment of a disease or condition that can be ameliorated by antagonizing a P2Y1 receptor, for example, platelet aggregation, atherosclerosis or thrombosis. The invention also provides conjugates comprising a P2Y1 antagonist that is covalently linked to a conjugant such as a dendrimer.

  该发明提供了化合物（I）的P2Y1受体拮抗剂；其中R1-R3如规范中所定义，包括相同的药物组合物，并且利用这种拮抗剂用于治疗可以通过拮抗P2Y1受体改善的疾病或症状，例如血小板聚集、动脉粥样硬化或血栓形成。该发明还提供了包括P2Y1拮抗剂的共轭物，该拮抗剂与共轭物如树状分子等共价连接。
• Synthesis of 2-aralkyloxyadenosines, 2-alkoxyadenosines, and their analogs
  申请人：King Pharmaceuticals Research and Development, Inc.

  公开号：US07342003B2

  公开（公告）日：2008-03-11

  Provided is a method for the synthesis of an aralkyloxyadenosine or an alkoxyadenosine. The method includes protecting the hydroxyl sugar groups with a protecting group to produce a protected halogenated adenosine. The protected halogenated adenosine is alkoxylated, and the hydroxyl sugar groups of the protected halogenated adenosine are deprotected to provide the aralkyloxyadenosine or alkoxyadenosine.

  提供的是一种合成芳基氧基腺苷或烷氧基腺苷的方法。该方法包括使用保护基保护羟基糖基，以产生受保护的卤代腺苷。将受保护的卤代腺苷烷氧化，并去除其保护基，以提供芳基氧基腺苷或烷氧基腺苷。
• Pyrazine Derivatives Useful as Adenosine Receptor Antagonists
  申请人：Vidal Juan Bernat

  公开号：US20090042891A1

  公开（公告）日：2009-02-12

  The present disclosure relates to a compound of formula (I) wherein: A is an optionally substituted monocyclic or polycyclic aryl or heteroaryl group; B is an optionally substituted monocyclic nitrogen-containing heteroaryl group; and either a) R 1 and R 2 are chosen from a hydrogen atom and specified substituents, or b) R 2 , R 1 and the —NH— group to which R 1 is attached, form a moiety chosen from the moiety of formulae (IIa) and (IIb): or a pharmaceutically acceptable salt thereof, or a N-oxide thereof. The present disclosure also relates to a method for treating a subject afflicted with a pathological condition or disease susceptible to amelioration by antagonism of the A 2B adenosine receptor.

  本公开涉及一种式（I）的化合物，其中：A是可选取的取代的单环或多环芳基或杂芳基基团；B是可选取的取代的单环含氮杂芳基基团；并且要么a）R1和R2选择自氢原子和指定的取代基，要么b）R2、R1和R1附着的—NH—基团形成式（IIa）和（IIb）的基团：或其药学上可接受的盐或其N-氧化物。本公开还涉及一种治疗患有病理状况或疾病，易于通过拮抗A2B腺苷受体而改善的受试者的方法。